Anti-I™2B/ ABRI/ BRI monoclonal antibody

Anti-I™2B/ ABRI/ BRI antibody for FACS & in-vivo assay

Target products collectionGo to I™2B/I™2B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0641-Ab-1/ GM-Tg-hg-MP0641-Ab-2Anti-Human I™2B monoclonal antibodyHuman
GM-Tg-rg-MP0641-Ab-1/ GM-Tg-rg-MP0641-Ab-2Anti-Rat I™2B monoclonal antibodyRat
GM-Tg-mg-MP0641-Ab-1/ GM-Tg-mg-MP0641-Ab-2Anti-Mouse I™2B monoclonal antibodyMouse
GM-Tg-cynog-MP0641-Ab-1/ GM-Tg-cynog-MP0641-Ab-2Anti-Cynomolgus/ Rhesus macaque I™2B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0641-Ab-1/ GM-Tg-felg-MP0641-Ab-2Anti-Feline I™2B monoclonal antibodyFeline
GM-Tg-cang-MP0641-Ab-1/ GM-Tg-cang-MP0641-Ab-2Anti-Canine I™2B monoclonal antibodyCanine
GM-Tg-bovg-MP0641-Ab-1/ GM-Tg-bovg-MP0641-Ab-2Anti-Bovine I™2B monoclonal antibodyBovine
GM-Tg-equg-MP0641-Ab-1/ GM-Tg-equg-MP0641-Ab-2Anti-Equine I™2B monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0641-Ab-1/ GM-Tg-hg-MP0641-Ab-2; GM-Tg-rg-MP0641-Ab-1/ GM-Tg-rg-MP0641-Ab-2;
GM-Tg-mg-MP0641-Ab-1/ GM-Tg-mg-MP0641-Ab-2; GM-Tg-cynog-MP0641-Ab-1/ GM-Tg-cynog-MP0641-Ab-2;
GM-Tg-felg-MP0641-Ab-1/ GM-Tg-felg-MP0641-Ab-2; GM-Tg-cang-MP0641-Ab-1/ GM-Tg-cang-MP0641-Ab-2;
GM-Tg-bovg-MP0641-Ab-1/ GM-Tg-bovg-MP0641-Ab-2; GM-Tg-equg-MP0641-Ab-1/ GM-Tg-equg-MP0641-Ab-2
Products NameAnti-I™2B monoclonal antibody
Formatmab
Target NameI™2B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-I™2B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species I™2B/ ABRI/ BRI VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0641
    Target NameI™2B
    Gene ID9445,16432,290364,709896,476916,101101607,510575,100050288
    Gene Symbol and SynonymsABRI,BRI,BRI2,BRICD2B,D14Sel6,E25B,E25BMM,E3-16,FBD,imBRI2,I™2B,RDGCA
    Uniprot AccessionQ9Y287,Q5XIE8,Q3T0P7
    Uniprot Entry NameI™2B_HUMAN,I™2B_RAT,I™2B_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000136156
    Target ClassificationN/A

    The target: I™2B, gene name: I™2B, also named as ABRI, BRI, BRI2, BRICD2B, E25B, E3-16, FBD, RDGCA, imBRI2. Amyloid precursor proteins are processed by beta-secretase and gamma-secretase to produce beta-amyloid peptides which form the characteristic plaques of Alzheimer disease. This gene encodes a transmembrane protein which is processed at the C-terminus by furin or furin-like proteases to produce a small secreted peptide which inhibits the deposition of beta-amyloid. Mutations which result in extension of the C-terminal end of the encoded protein, thereby increasing the size of the secreted peptide, are associated with two neurogenerative diseases, familial British dementia and familial Danish dementia. [provided by RefSeq, Oct 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.